CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Neurocrine Biosciences, Inc. - NBIX CFD

    119.37
    1.02%
    0.50
    Low: 117.45
    High: 119.87
    Market Trading Hours* (UTC) Opens on Thursday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.50
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Neurocrine Biosciences Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 118.16
    Open* 117.45
    1-Year Change* -4.91%
    Day's Range* 117.45 - 119.87
    52 wk Range 89.04-129.29
    Average Volume (10 days) 732.62K
    Average Volume (3 months) 14.23M
    Market Cap 10.77B
    P/E Ratio 58.62
    Shares Outstanding 98.25M
    Revenue 1.78B
    EPS 1.87
    Dividend (Yield %) N/A
    Beta 0.38
    Next Earnings Date Feb 5, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 118.16 2.47 2.14% 115.69 118.61 114.89
    Dec 4, 2023 116.09 -0.15 -0.13% 116.24 117.55 115.36
    Dec 1, 2023 116.63 0.12 0.10% 116.51 117.70 115.44
    Nov 30, 2023 116.48 3.49 3.09% 112.99 116.91 112.99
    Nov 29, 2023 113.11 2.23 2.01% 110.88 114.05 110.86
    Nov 28, 2023 112.34 -0.03 -0.03% 112.37 112.95 111.62
    Nov 27, 2023 112.85 1.48 1.33% 111.37 113.10 110.34
    Nov 24, 2023 112.00 1.80 1.63% 110.20 112.19 110.20
    Nov 22, 2023 110.55 0.99 0.90% 109.56 111.70 109.56
    Nov 21, 2023 109.26 1.50 1.39% 107.76 110.90 107.75
    Nov 20, 2023 109.31 1.96 1.83% 107.35 109.94 107.35
    Nov 17, 2023 108.56 0.63 0.58% 107.93 109.55 107.88
    Nov 16, 2023 108.23 -1.38 -1.26% 109.61 109.87 107.60
    Nov 15, 2023 110.31 -1.65 -1.47% 111.96 112.72 110.20
    Nov 14, 2023 112.16 1.31 1.18% 110.85 114.44 110.85
    Nov 13, 2023 109.80 3.76 3.55% 106.04 110.27 105.81
    Nov 10, 2023 106.76 0.43 0.40% 106.33 108.11 102.85
    Nov 9, 2023 112.06 -2.90 -2.52% 114.96 115.17 111.54
    Nov 8, 2023 114.94 -1.31 -1.13% 116.25 117.29 114.43
    Nov 7, 2023 116.36 2.39 2.10% 113.97 117.24 113.15

    Neurocrine Biosciences, Inc. Events

    Time (UTC) Country Event
    Monday, February 5, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Neurocrine Biosciences Inc Earnings Release
    Q4 2023 Neurocrine Biosciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1488.7 1133.5 1045.9 788.087 451.24
    Revenue 1488.7 1133.5 1045.9 788.087 451.24
    Total Operating Expense 1309.7 1031 901.3 715.804 414.345
    Selling/General/Admin. Expenses, Total 751 583.3 433.3 354.062 248.932
    Research & Development 463.8 328.1 275 200.042 160.524
    Operating Income 179 102.5 144.6 72.283 36.895
    Interest Income (Expense), Net Non-Operating 34.9 -1.1 -37.9 -25.741 -15.054
    Gain (Loss) on Sale of Assets
    Other, Net
    Net Income Before Taxes 213.9 101.4 106.7 46.542 21.841
    Net Income After Taxes 154.5 89.6 407.3 37.012 21.111
    Net Income Before Extra. Items 154.5 89.6 407.3 37.012 21.111
    Net Income 154.5 89.6 407.3 37.012 21.111
    Income Available to Common Excl. Extra. Items 154.5 89.6 407.3 37.012 21.111
    Income Available to Common Incl. Extra. Items 154.5 89.6 407.3 37.012 21.111
    Diluted Net Income 154.5 89.6 407.3 37.012 21.111
    Diluted Weighted Average Shares 98.9 97.9 97.8 95.732 95.386
    Diluted EPS Excluding Extraordinary Items 1.56218 0.91522 4.16462 0.38662 0.22132
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS 2.08583 1.86564 5.38021 1.66815 0.22132
    Cost of Revenue, Total 23.2 14.3 10.1 7.428 4.889
    Gross Profit 1465.5 1119.2 1035.8 780.659 446.351
    Unusual Expense (Income) 71.7 105.3 182.9 154.272
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 452.7 420.4 412 387.9 378.2
    Revenue 452.7 420.4 412 387.9 378.2
    Cost of Revenue, Total 11.5 8.5 7.7 6.1 4.8
    Gross Profit 441.2 411.9 404.3 381.8 373.4
    Total Operating Expense 379.1 534.6 308.6 300.1 393.5
    Selling/General/Admin. Expenses, Total 221.8 242.7 182.9 186.3 182.8
    Research & Development 145.8 139.5 118 107.7 135.9
    Operating Income 73.6 -114.2 103.4 87.8 -15.3
    Interest Income (Expense), Net Non-Operating 48 10.9 14.5 10.1 -8
    Net Income Before Taxes 121.6 -103.3 117.9 97.9 -23.3
    Net Income After Taxes 95.5 -76.6 89 68.5 -16.9
    Net Income Before Extra. Items 95.5 -76.6 89 68.5 -16.9
    Net Income 95.5 -76.6 89 68.5 -16.9
    Income Available to Common Excl. Extra. Items 95.5 -76.6 89 68.5 -16.9
    Income Available to Common Incl. Extra. Items 95.5 -76.6 89 68.5 -16.9
    Diluted Net Income 95.5 -76.6 89 68.5 -16.9
    Diluted Weighted Average Shares 100.2 97.1 100.7 99 95.6
    Diluted EPS Excluding Extraordinary Items 0.95309 -0.78888 0.88381 0.69192 -0.17678
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.95309 0.17441 0.88381 0.69192 0.29916
    Unusual Expense (Income) 0 143.9 0 0 70
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1453.5 972.8 1016.2 831.034 737.777
    Cash and Short Term Investments 989.3 711.3 801 670.524 650.913
    Cash & Equivalents 262.9 340.8 187.1 112.279 141.714
    Short Term Investments 726.4 370.5 613.9 558.245 509.199
    Other Current Assets, Total 79.1 45.5 30.1 16.647 18.594
    Total Assets 2368.7 2072.5 1734.7 1306.04 993.151
    Property/Plant/Equipment, Total - Net 145.6 155.8 127.4 116.278 33.869
    Property/Plant/Equipment, Total - Gross 211.9 207.7 169.1 149.837 62.14
    Accumulated Depreciation, Total -66.3 -51.9 -41.7 -33.559 -28.271
    Long Term Investments 401.5 624.4 265.3 355.522 216.028
    Other Long Term Assets, Total 330.9 319.5 325.8 3.206 5.477
    Total Current Liabilities 537.7 245.8 186.5 565.287 88.233
    Accounts Payable 46.214 38.381
    Accrued Expenses 129.3 99.5 81.4 72.719 34.41
    Notes Payable/Short Term Debt 0 0 0 408.807 0
    Other Current Liabilities, Total 3.3 3.5 7.5 37.547 15.442
    Total Liabilities 660.9 698.5 608.5 669.117 512.386
    Total Long Term Debt 0 335.1 317.9 0 388.496
    Other Liabilities, Total 123.2 117.6 104.1 103.83 35.657
    Total Equity 1707.8 1374 1126.2 636.923 480.765
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.1 0.1 0.1 0.092 0.091
    Additional Paid-In Capital 2122.4 2011.4 1849.7 1768.12 1660.36
    Retained Earnings (Accumulated Deficit) -406.8 -635.8 -725.4 -1132.7 -1177.76
    Other Equity, Total -7.9 -1.7 1.8 1.413 -1.932
    Total Liabilities & Shareholders’ Equity 2368.7 2072.5 1734.7 1306.04 993.151
    Total Common Shares Outstanding 96.5 94.9 93.5 92.272 90.797
    Total Receivables, Net 350 185.5 157.1 126.575 57.406
    Accounts Receivable - Trade, Net 350 185.5 157.1 126.575 57.406
    Long Term Debt 0 335.1 317.9 0 388.496
    Total Inventory 35.1 30.5 28 17.288 10.864
    Payable/Accrued 235.7 142.8 97.6
    Intangibles, Net 37.2
    Current Port. of LT Debt/Capital Leases 169.4
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 1649.9 1496.6 1432.8 1453.5 1205.5
    Cash and Short Term Investments 1095.1 976.7 894.6 989.3 799.4
    Cash & Equivalents 293.7 160.2 103.8 262.9 212.2
    Short Term Investments 801.4 816.5 790.8 726.4 587.2
    Total Receivables, Net 417.8 387.6 391.6 350 301.2
    Accounts Receivable - Trade, Net 417.8 387.6 391.6 350 301.2
    Total Inventory 28.8 31.7 33.4 35.1 37
    Other Current Assets, Total 108.2 100.6 113.2 79.1 67.9
    Total Assets 2848.2 2613.1 2359.8 2368.7 2143.4
    Property/Plant/Equipment, Total - Net 149.6 149.1 147.2 145.6 150.5
    Long Term Investments 587.5 515.6 380.3 401.5 457.5
    Other Long Term Assets, Total 426.3 414.9 362.3 330.9 329.9
    Total Current Liabilities 691.6 582.5 374.1 537.7 485.1
    Payable/Accrued 394.9 391.6 355.7 347.6 297.8
    Accrued Expenses 125.9 17.7 17.6 17.4 17.3
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.9 3.5 0.8 3.3 0.8
    Total Liabilities 846.1 760.1 675.3 660.9 598.8
    Total Long Term Debt 0 0 169.5 0 0
    Long Term Debt 169.5 0 0
    Other Liabilities, Total 154.5 177.6 131.7 123.2 113.7
    Total Equity 2002.1 1853 1684.5 1707.8 1544.6
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.1 0.1 0.1 0.1 0.1
    Additional Paid-In Capital 2308.5 2241.9 2170.5 2122.4 2054.3
    Retained Earnings (Accumulated Deficit) -304.8 -387.9 -483.4 -406.8 -495.8
    Other Equity, Total -1.7 -1.1 -2.7 -7.9 -14
    Total Liabilities & Shareholders’ Equity 2848.2 2613.1 2359.8 2368.7 2143.4
    Total Common Shares Outstanding 98.2 97.6 97.5 96.5 96.1
    Current Port. of LT Debt/Capital Leases 169.9 169.7 0 169.4 169.2
    Intangibles, Net 34.9 36.9 37.2 37.2
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 154.5 89.6 407.3 37.012 21.111
    Cash From Operating Activities 339.4 256.5 228.5 152.054 101.364
    Cash From Operating Activities 15.1 10.9 8.6 7.452 4.024
    Non-Cash Items 217.6 135 161.2 107.349 77.986
    Cash Interest Paid 6.6 8.6 11.6 11.644 11.644
    Changes in Working Capital -67.4 16.7 -37.9 0.241 -1.757
    Cash From Investing Activities -177.1 -130.2 4.1 -211.073 -242.915
    Capital Expenditures -16.5 -23.4 -10.9 -14.748 -24.812
    Other Investing Cash Flow Items, Total -160.6 -106.8 15 -196.325 -218.103
    Cash From Financing Activities -234.3 27.4 -157.8 27.313 29.53
    Issuance (Retirement) of Stock, Net 44.7 27.5 29.1 27.313 29.53
    Issuance (Retirement) of Debt, Net -279 -0.1 -186.9 0 0
    Net Change in Cash -73.3 153.7 74.8 -31.706 -112.021
    Cash Taxes Paid 14.4 5.1 15.3 0.507
    Deferred Taxes 19.1 4.3 -310.7
    Amortization 0.5
    Foreign Exchange Effects -1.3
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -76.6 154.5 65.5 -3 13.9
    Cash From Operating Activities -125.2 339.4 196.4 97.6 -40.5
    Cash From Operating Activities 4.1 15.1 11.2 7.2 3.3
    Deferred Taxes -31.6 19.1 5.6 -3.4 -0.3
    Non-Cash Items 35.5 217.6 180 147.1 18.3
    Changes in Working Capital -57.5 -67.4 -65.9 -50.3 -75.7
    Cash From Investing Activities -42.1 -177.1 -61.5 -0.2 -31.6
    Capital Expenditures -8.5 -16.5 -14.7 -16.4 -7.6
    Other Investing Cash Flow Items, Total -33.6 -160.6 -46.8 16.2 -24
    Cash From Financing Activities 8.2 -234.3 -258.9 -270.3 6.1
    Issuance (Retirement) of Stock, Net 8.2 44.7 20.1 8.7 6.1
    Issuance (Retirement) of Debt, Net -279 -279 -279 0
    Net Change in Cash -159.1 -73.3 -124 -172.9 -66
    Cash Taxes Paid 0.2 14.4 4.3 3.1
    Cash Interest Paid 6.6 4.6 4.6
    Amortization 0.9 0.5
    Foreign Exchange Effects -1.3
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BlackRock Institutional Trust Company, N.A. Investment Advisor 10.6161 10366912 220306 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.76 9530883 -26814 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.0516 3956499 156584 2023-06-30 LOW
    Bellevue Asset Management AG Investment Advisor 2.6756 2612800 -500 2023-06-30 LOW
    Janus Henderson Investors Investment Advisor/Hedge Fund 1.9547 1908844 -85677 2023-06-30 LOW
    Armistice Capital LLC Hedge Fund 1.6897 1650000 58000 2023-06-30 MED
    Renaissance Technologies LLC Hedge Fund 1.6829 1643402 -303662 2023-06-30 HIGH
    JP Morgan Asset Management Investment Advisor 1.6353 1596880 -54369 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.56 1523408 87671 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.4331 1399439 228393 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 1.3377 1306273 831881 2023-06-30 LOW
    Rock Springs Capital Management LP Hedge Fund 1.3103 1279500 69400 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 1.2666 1236839 -61520 2023-06-30 LOW
    Deerfield Management Company, L.P. Hedge Fund 1.2388 1209714 -535000 2023-06-30 MED
    Amundi Asset Management, SAS Investment Advisor/Hedge Fund 1.2186 1190026 -30338 2023-06-30 LOW
    Woodline Partners LP Hedge Fund 1.1799 1152189 753495 2023-06-30 HIGH
    American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.1308 1104267 242362 2023-06-30 LOW
    Brown Advisory Investment Advisor/Hedge Fund 1.1158 1089582 -10274 2023-09-30 LOW
    DSM Capital Partners, LLC Investment Advisor 1.0858 1060270 -199261 2023-06-30 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.016 992153 -119041 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Neurocrine Company profile

    About Neurocrine Biosciences, Inc.

    Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).

    Equity composition

    Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.

    Industry: Bio Therapeutic Drugs

    12780 El Camino Real
    SAN DIEGO
    CALIFORNIA 92130-2042
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Gold

    2,028.26 Price
    +0.370% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    43,922.25 Price
    -0.160% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    15,800.20 Price
    -0.510% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    XRP/USD

    0.64 Price
    +2.700% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading